alexa Abstract | Propranolol Decreases the Viability and Triggers Apoptosis in Hemangioblastoma Cells from Von Hippel-Lindau Patients
ISSN: 2376-0389

Journal of Multiple Sclerosis
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Commentary Open Access

Abstract

Abstract

In our previous paper, propranolol is used in hemangioblastomas primary cultures from patients with von Hippel- Lindau disease. This is a rare inherited oncologic condition characterized by the growth of tumors affecting mainly the central nervous system, but also kidneys, pancreas, adrenal glands, retinas and endolymphatic sacs (inner ear). Up to date, the only treatment for these patients is surgery. The search for drugs able, at least, to stop the development of hemangioblastomas, has led our group to propose propranolol, a non-specific beta blocker, as a drug to test. According to the results of this work, propranolol would act by decreasing hypoxia signaling pathway, which is constitutively active in VHL patients, normalizing the hypoxia target genes involved in angiogenesis, survival and stemness in the hemangioblastoma cells. The results in vitro are promising and, in the absence of serious side effects, propranolol could be assayed as a therapy in the clinical practice for VHL patients.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Luisa María Botella,Virginia Albinana, Karina Villar Gómez de las Heras and Mercedes Mota-Perez

Keywords

Von Hippel-Lindau disease (VHL), PVHL, Hypoxia inducible factor, Hemangioblastoma, CNS tumors, Propranolol, Von Hippel-Lindau disease (VHL), PVHL, Hypoxia inducible factor, Hemangioblastoma, CNS tumors, Propranolol

Share This Page

Additional Info

Loading
Loading Please wait..
 
 
 
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords